

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF TRANSMITTAL
OF COPIES OF TRANSLATION
OF THE INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY
(CHAPTER I OR CHAPTER II
OF THE PATENT COOPERATION TREATY)
(PCT Rules 44bis.3(c) and 72.2)

Date of mailing (day/month/year)
31 August 2006 (31.08.2006)

To:

IWATANI, Ryo
ORIX Dojima Bldg. 3F
1-31, Dojima 2-chome, Kita-ku
Osaka-shi, Osaka 530-0003
JAPON



IMPORTANT NOTIFICATION

Applicant's or agent's file reference

O07F1533

International application No.

PCT/JP2004/019400

International filing date (day/month/year)

24 December 2004 (24.12.2004)

Applicant

ONO PHARMACEUTICAL CO., LTD. et al

1. Transmittal of the translation to the applicant.



The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter I).



The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter II).

2. Transmittal of the copy of the translation to the designated or elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following designated or elected Offices requiring such translation:

None

The following designated or elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AE, AG, AL, AM, AP, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EA, EC, EE, EG, EP, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability (Chapter II).

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned within the applicable time limit (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. +41 22 338 82 70

Authorized officer

Yoshiko Kuwahara

Facsimile No. +41 22 338 82 70

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference O07F1533	FOR FURTHER ACTION		See item 4 below
International application No. PCT/JP2004/019400	International filing date (<i>day/month/year</i>) 24 December 2004 (24.12.2004)	Priority date (<i>day/month/year</i>) 25 December 2003 (25.12.2003)	
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237			
Applicant ONO PHARMACEUTICAL CO., LTD.			

<p>1. This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).</p> <p>2. This REPORT consists of a total of 7 sheets, including this cover sheet.</p> <p>In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.</p>																								
<p>3. This report contains indications relating to the following items:</p> <table> <tbody> <tr> <td><input checked="" type="checkbox"/></td> <td>Box No. I</td> <td>Basis of the report</td> </tr> <tr> <td><input type="checkbox"/></td> <td>Box No. II</td> <td>Priority</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>Box No. III</td> <td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td><input type="checkbox"/></td> <td>Box No. IV</td> <td>Lack of unity of invention</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>Box No. V</td> <td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>Box No. VI</td> <td>Certain documents cited</td> </tr> <tr> <td><input type="checkbox"/></td> <td>Box No. VII</td> <td>Certain defects in the international application</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>Box No. VIII</td> <td>Certain observations on the international application</td> </tr> </tbody> </table> <p>4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis .2).</p>	<input checked="" type="checkbox"/>	Box No. I	Basis of the report	<input type="checkbox"/>	Box No. II	Priority	<input checked="" type="checkbox"/>	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	<input type="checkbox"/>	Box No. IV	Lack of unity of invention	<input checked="" type="checkbox"/>	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	<input checked="" type="checkbox"/>	Box No. VI	Certain documents cited	<input type="checkbox"/>	Box No. VII	Certain defects in the international application	<input checked="" type="checkbox"/>	Box No. VIII	Certain observations on the international application
<input checked="" type="checkbox"/>	Box No. I	Basis of the report																						
<input type="checkbox"/>	Box No. II	Priority																						
<input checked="" type="checkbox"/>	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																						
<input type="checkbox"/>	Box No. IV	Lack of unity of invention																						
<input checked="" type="checkbox"/>	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																						
<input checked="" type="checkbox"/>	Box No. VI	Certain documents cited																						
<input type="checkbox"/>	Box No. VII	Certain defects in the international application																						
<input checked="" type="checkbox"/>	Box No. VIII	Certain observations on the international application																						

Date of issuance of this report 22 August 2006 (22.08.2006)	
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. +41 22 338 82 70	Authorized officer Yoshiko Kuwahara e-mail: pt07@wipo.int

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

To:

PCT

TRANSLATION

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Applicant's or agent's file reference 007F1533		Date of mailing (day/month/year)	
International application No. PCT/JP2004/019400		FOR FURTHER ACTION See paragraph 2 below	Priority date (day/month/year) 25.12.2003
International Patent Classification (IPC) or both national classification and IPC			
Applicant ONO PHARMACEUTICAL CO., LTD.			

1. This opinion contains indications relating to the following items:

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application

2. **FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/JP	Authorized officer
Facsimile No.	Telephone No.

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/JP2004/019400

Box No. I Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 This opinion has been established on the basis of a translation from the original language into the following language _____, which is the language of a translation furnished for the purposes of international search (under Rule 12.3 and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
 - a. type of material
 a sequence listing
 table(s) related to the sequence listing
 - b. format of material
 in written format
 in computer readable form
 - c. time of filing/furnishing
 contained in the international application as filed.
 filed together with the international application in computer readable form.
 furnished subsequently to this Authority for the purposes of search.
3. In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/JP2004/019400

Box No. III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

the entire international application
 claims Nos. 17

because:

the said international application, or the said claims Nos. 17
relate to the following subject matter which does not require an international preliminary examination (specify):

The inventions of Claims 17 involve a method for treatment of the human body by therapy, which does not require an international preliminary examination.

the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _____ are so unclear that no meaningful opinion could be formed (specify):

the claims, or said claims Nos. _____ are so inadequately supported by the description that no meaningful opinion could be formed.

no international search report has been established for said claims Nos. 17

the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:

the written form has not been furnished
 does not comply with the standard

the computer readable form has not been furnished
 does not comply with the standard

the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.

See Supplemental Box for further details.

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/JP2004/019400

Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																										
<p>1. Statement</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%;">Novelty (N)</td> <td style="width: 40%;">Claims</td> <td>3, 5-8, 10-16, 18, 19</td> <td style="width: 15%; text-align: center;">YES</td> </tr> <tr> <td></td> <td>Claims</td> <td>1, 2, 4, 9</td> <td style="text-align: center;">NO</td> </tr> <tr> <td style="width: 25%;">Inventive step (IS)</td> <td style="width: 40%;">Claims</td> <td>3, 5-8, 10-16, 18, 19</td> <td style="width: 15%; text-align: center;">YES</td> </tr> <tr> <td></td> <td>Claims</td> <td>1, 2, 4, 9</td> <td style="text-align: center;">NO</td> </tr> <tr> <td style="width: 25%;">Industrial applicability (IA)</td> <td style="width: 40%;">Claims</td> <td>1-16, 18, 19</td> <td style="width: 15%; text-align: center;">YES</td> </tr> <tr> <td></td> <td>Claims</td> <td>17</td> <td style="text-align: center;">NO</td> </tr> </table>				Novelty (N)	Claims	3, 5-8, 10-16, 18, 19	YES		Claims	1, 2, 4, 9	NO	Inventive step (IS)	Claims	3, 5-8, 10-16, 18, 19	YES		Claims	1, 2, 4, 9	NO	Industrial applicability (IA)	Claims	1-16, 18, 19	YES		Claims	17	NO
Novelty (N)	Claims	3, 5-8, 10-16, 18, 19	YES																								
	Claims	1, 2, 4, 9	NO																								
Inventive step (IS)	Claims	3, 5-8, 10-16, 18, 19	YES																								
	Claims	1, 2, 4, 9	NO																								
Industrial applicability (IA)	Claims	1-16, 18, 19	YES																								
	Claims	17	NO																								
<p>2. Citations and explanations:</p> <p>Document 1: US 6335324 B1 (Bristol-Myers Squibb Co.), 01 January 2002 Document 2: WO 99/67215 A1 (Bristol-Myers Squibb Co., USA), 29 December 1999 Document 3: US 5849780 A (Sanofi, France), 15 December 1998 Document 4: JP 6-41131 A (Sankyo Company, Limited), 15 February 1994</p>																											
<p>Claims 1, 2, 4 and 9</p> <p>Document 1 cited in the ISR describes the compound of Claim 1 wherein X is an oxygen atom, R1 is a hydrogen atom, R2 is an optionally substituted hydrocarbon group, and R3 and R4 are nitrogen-containing heterocyclic groups having substitutional groups together with adjacent nitrogen atoms, and describes a drug application as an application therefor. Document 2 describes the compound of Claim 1 wherein X is an oxygen atom, R1 is a hydrogen atom, R2 is a hydrogen atom, and R3 and R4 are nitrogen-containing heterocyclic groups having substitutional groups together with adjacent nitrogen atoms, and describes a drug application as a an application therefor. Document 3 describes the compound of Claim 1 wherein X is an oxygen atom, R1 is a hydrogen atom, R2 is an optionally substituted hydrocarbon group, R3 is a hydrogen atom and R4 is a substituted phenyl group, and describes a drug application as a an application therefor. Document 4 describes the compound of Claim 1 wherein X is an optionally substituted nitrogen atom, R1 is a hydrogen atom, R2 is an optionally substituted hydrocarbon group, and R3 and R4 are hydrogen atoms, and describes a drug application as a an application therefor.</p> <p>Consequently, the inventions of Claims 1 and 9 do not appear to be novel or to involve an inventive step over documents 1, 2, 3 and 4 cited in the ISR. The invention of Claim 2 does not appear to be novel or to involve an inventive step over documents 1, 2 and 3 cited in the ISR. The invention of Claim 4 does not appear to be novel or to involve an inventive step over document 3 cited in the ISR.</p> <p>Claims 3, 5-8, 10-16, 18, 19</p> <p>The inventions of 3, 5-8, 10-16, 18 and 19 are neither described nor suggested in any of the documents cited in the ISR.</p>																											

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/JP2004/019400

Box No. VI	Certain documents cited			
1. Certain published documents (Rule 43bis.1 and 70.10)				
	Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
	JP 2004-277320 A [E, X]	07.10.2004	14.03.2003	
	WO 2004/39814 A1 [E, X]	13.05.2004	27.10.2003	30.10.2002
	WO 2004/2531 A1 [E, X]	01.08.2004	25.06.2003	26.06.2002
2. Non-written disclosures (Rule 43bis.1 and 70.9)				
	Kind of non-written disclosure	Date of non-written disclosure (day/month/year)	Date of written disclosure referring to non-written disclosure (day/month/year)	

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/JP2004/019400

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The invention described in Claim 19 relates to a method of manufacturing the compound represented by general formula (I) in Claim 1 and the like, but it is not described clearly because there is no description of specific matters required for a manufacturing method.